Clinical Trial

THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
Protocol Amendment History 4 changes
notable Primary completion moved earlier: 2030-09-01 -> 2029-09-01 2026-07-08
minor Completion moved earlier: 2031-08-01 -> 2030-09-01 2026-07-08
notable Primary completion pushed: 2030-05-01 -> 2030-09-01 2026-07-03
minor Completion pushed: 2031-05-01 -> 2031-08-01 2026-07-03
Trial Details
NCT Number NCT07446257
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: Maia Biotechnology, National Cancer Institute (NCI)
Conditions Resectable Hepatocellular Carcinoma
Enrollment 60 participants
Start Date 2026-06-29
Primary Completion 2029-09-01 (estimated)
Study Completion 2030-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-07